DEVELOPMENTAL CHEMOTHERAPY

描述：(申请人的描述)化疗仍然是 癌症治疗的主要手段。在过去的30年里，这笔赠款 允许纪念医院快速测试和应用新的治疗方法 各种癌症。该项目的总体目标将是进行阶段 I在纪念馆开发的新的单一药物和联合疗法的研究 医院申请疾病特异性第二阶段和第三阶段试验。 新研究的重点将放在想法和化合物上 在纪念斯隆·凯特琳癌症中心内开发，我们为该中心举办 Ind.将要进行的临床试验将包括这两个分子 适当时的反应和药代动力学标记物。此案中的所有审判 项目为第一阶段研究。在该项目中进行的临床试验 将被分成3个具体目标。具体目标1是开发 包括格尔达霉素类似物10-炔丙基-10的新型药物 脱氮氨基蝶呤、三氧化二砷、PS341和脱氧泊硫酮B 目标二是使用吡咯酰胺的靶向治疗计划， 在这种推定的分化因子的开发中。最后，在 具体目的3描述了支持这些试验的相关科学。每个人 的临床研究将与药代动力学和分子生物学有关 实验室相关研究。通过这项工作，我们希望发现新的， 更积极的治疗方法，以成功地管理人类恶性肿瘤。

DESCRIPTION: (Applicant's Description) Chemotherapy remains one of the principal means of cancer treatment. Over the past 3 decades, this grant has allowed Memorial Hospital to rapidly test and apply new treatments to a variety of cancers. The overall goal of this project will be to conduct Phase I studies of new single agents and combination therapies developed at Memorial Hospital for application in disease specific Phase II and Phase III trials. Highest priority for new studies will be given to ideas and compounds developed within the Memorial Sloan Kettering Cancer Center for which we hold the IND. The clinical trials to be performed will include both molecular markers of response and pharmacokinetics when appropriate. All trials in this project are Phase I studies. The clinical trials performed in this project will be grouped into 3 specific aims. Specific aim 1 is the development of novel agents including geldanamycin analogs, 10 - propargyl-10 deazaaminopterin, arsenic trioxide, PS341, and desoxyepothilone B. Specific Aim Two is a target based therapy program utilizing Pyroxamide and is directed at the development of this putative differentiation agent. Finally, in Specific aim 3 correlative science is described to support these trials. Each of these clinical studies will be linked to pharmacokinetic and molecular laboratory correlative studies. Through this work, we expect to identify new, more active treatments for the successful management of human malignancies.